Log in to search using one of your social media accounts:

 

Association of Catechol-O-methyltransferase polymorphism Val158Met and mammographic density: A meta-analysis.

CONCLUSIONS: COMT Val158Met polymorphism may be associated with mammographic density at least in healthy women. Menopausal status and HRT should be taken into account in future studies to avoid masking of the underlying effects. PMID: 28473194 [PubMed - as supplied by publisher]
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research

Related Links:

It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
(Natural News) Hormone replacement therapy is often touted for any number of things; these kinds of drugs are often given to women under the guise of reducing heart disease risk and minimizing the effects of menopause, for example. But are they really safe? While hormone replacement therapy (HRT) first gained popularity for reducing signs of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor overexpression are recognized mechanisms of endocrin...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Commentary Source Type: research
A study this week concluded HRT does not shorten lives – but it still increases the risk of cancer, leaving those suffering symptoms with a tough choice to makeHormone replacement therapy (HRT), possibly the most controversial medicine ever invented,will not kill you. That was theconclusion this week of a big, respectable study in the United States that was one of the first to flag up the risk of breast cancer. Women who took the tablets to alleviate the hot flushes and night sweats that assail them, prevent them sleeping and can make life intolerable were no more likely to be dead 18 years later than women who did n...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Menopause Medical research Women Health Science Society & wellbeing Source Type: news
CONCLUSIONS: Both general and central obesity contribute to breast cancer risk, with different effects on specific subtypes. General obesity, indicated by BMI, is more strongly associated with ER+/PR+ subtype, especially among premenopausal women, whereas central obesity, indicated by WHR, is more specific for ER-/PR- subtype, independent of menopausal status. These results suggest that different chemoprevention strategies may be appropriate in selected individuals. IMPLICATIONS FOR PRACTICE: The results of this study suggest that general and central obesity may play different roles in different breast cancer subtypes...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
AbstractPurposeTo evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk.MethodsA cohort of all Maccabi Healthcare Services (MHS) female members aged 40 –50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as “cases,” and 2 age-matched non-users as “controls.” Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen. Invasiv e tumors were characterized by treatments received (chemotherapy, hormonal therapy,...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionThe association of weight loss prior to ET and subsequent substantial weight gain during ET warrants further investigation.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The pendulum has swung from one extreme to the other when it comes to hormone replacement therapy (HRT) to treat symptoms of menopause. At first, the replacement hormones—mostly a combination of estrogen and progestin to replace what the body stops making after menopause—were seen as a panacea. Doctors thought they could not only relieve hot flashes and night sweats, but also prevent chronic aging diseases like heart problems and weakening bones. But studies then found that the supplement hormones could lead to a higher risk of breast cancer—and that they didn’t protect the heart after all. In the l...
Source: TIME.com: Top Science and Health Stories - Category: Consumer Health News Authors: Tags: Uncategorized Drugs estrogen Hormone Therapy hormones for menopause hot flashes night sweats progestin Reproductive Health treating menopause Source Type: news
Conclusion: Use of several organophosphate insecticides was associated with elevated breast cancer risk. However, associations for the women’s and husbands’ use of these insecticides showed limited concordance. Ongoing cohort follow-up may help clarify the relationship, if any, between individual insecticide exposures and breast cancer risk. https://doi.org/10.1289/EHP1295 Received: 28 October 2016 Revised: 25 April 2017 Accepted: 08 May 2017 Published: 06 September 2017 Address correspondence to L. Engel, Dept. of Epidemiology, University of North Carolina, CB #7435, Chapel Hill, NC 27599-7435 USA. Telep...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Abstract INTRODUCTION: The introduction of CDK4/6 inhibitors, such as ribociclib, has changed the treatment landscape for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. As first-line treatment of HR+/HER2- MBC, the addition of a CDK4/6 inhibitor to an aromatase inhibitor improves progression-free survival compared to an aromatase inhibitor alone. Areas covered: In this drug profile, we review the current market for HR+/HER2- MBC, as well as the characteristics, mechanism, pharmacology, pharmacodynamics, pharmacokinetics, metabolism, clinical efficacy, toxicities, monitoring, and dosing ...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Hormone Replacement Therapy | Hormones | Mammography | Men | Menopause | Study | Women